C. Sposetti

Platinum sensitivity in patients with IDH1/2 mutated vs wild‐type intrahepatic cholangiocarcinoma: A propensity score‐based study

E. Vasile, V. Mazzaferro, M. Fassan, 2022, International journal of cancer.

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

G. Fucà, L. Provenzano, G. Capri, 2023, Therapeutic advances in medical oncology.

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

G. Curigliano, S. Gandini, M. Pistelli, 2023, European Journal of Cancer.

Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy

G. Fontanini, M. Fassan, M. Germani, 2022, JCO precision oncology.

Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: different biological and clinical entities with potentially diverse therapeutic opportunities.

S. Manoukian, G. Pruneri, A. Vingiani, 2023, Critical reviews in oncology/hematology.

Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

A. Vingiani, M. Dieci, G. Fucà, 2023, Therapeutic advances in medical oncology.

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study

A. Palazzo, Z. Ballatore, F. Pantano, 2023, The oncologist.

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

L. Mariani, G. Pruneri, A. Vingiani, 2023, NPJ breast cancer.